Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Form 483 Reply Can Be Ticket To FDA’s Good Side – Attorney

This article was originally published in The Tan Sheet

Executive Summary

Taking a conciliatory tone and showing a commitment to compliance can help a company avoid further enforcement action after receiving a form 483 from FDA that details “significant” inspectional observations, says food and drug attorney Kate Beardsley.


Related Content

After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
Timely 483 Response Can Ease Agency Enforcement Action – FDA Official





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts